

Cohort of Consultants from Health Examination Clinics

<https://neurodegenerationresearch.eu/survey/cohort-of-consultants-from-health-examination-clinics/>

Title of cohort

Cohort of Consultants from Health Examination Clinics

Acronym for cohort

CONSTANCES

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Marie

Name of Principal Investigator - Last name

Zins

Address of institution -Institution

INSERM-UVSQ UMS 11

Address of institution - Street address

INSERM-UVSQ UMS 11

Address of institution - City

VILLEJUIF

Address of institution - Postcode

94807

Country

France

Website

<http://www.constances.fr/>

Contact email

Funding source

CNAMTS, DGS, Ministry of Health, Youth, Sport and Community Life in the Île-de-France region, IReSP, ANR, Public/private partnership through INSERM Transfer).

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

The objective is to establish a major epidemiological representative cohort of the general population and large workforce, in order to contribute to the development of epidemiological research and to provide information regarding public health.

Q2b. What distinguishes this cohort from other population cohorts?

size, quality and diversity of data, monitoring methods

Q3a. i) Number of publications that involve use of your cohort to date

23

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

A. Elbaz, Inserm, Maladie de Parkinson : facteurs de risque et protecteurs| J-F. Dartigues, Inserm, Validation de cas de démence| S. Andrieu, Inserm, Big data et vieillissement

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

18

Q4a. Study criteria: what is the age range of participants at recruitment? To:

69

Q4b. Study criteria: what are the inclusion criteria?

Adults between 18 and 69 years old and affiliated with the General Social Security Fund.

Q4c. Study criteria: what are the exclusion criteria?

None

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000 participants

Q6a. Please describe what measures are used to characterise participants

Socioprofessionnal, lifestyle, environment, morbidity, health examination, cognitive tests

Q6b. Are there additional measures for participants with a clinical disorder?

Medical records for some conditions

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify

Q7. What is the study design (select all that apply)?

Prospective cohort|Longitudinal

Q8. Are your cases matched by

Other health assessment (not specified)

Q9a. Does your study include a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe

The whole cohort

Q10a. i) Please enter the data collection start date

01/06/2012

Q10a. ii) Please enter the data collection end date

Continuous; no end planned

Q10a. iii) Is data collection for this study

Data collection ongoing| Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected

Through links to other records or registers (e.g dental records, police records etc)

Other please specify here

Questionnaires, health examination

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Yes (participants given permission to be re-contacted via PIs)

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

No

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

No

% available

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available

Please specify language used

French and English

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| National access| International access| Access to industry| Access restricted to peer-reviewed work| Applicant needs to provide separate external ethics approval | Resource has own ethics approval so usually no need for separate external ethics approval

Q15. What data sharing policy is specified as a condition of use?

Data to be made publicly available immediately

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors blood| Living donors: blood derivatives| Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary Samples: Stabilised samples (frozen or fixed)

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients
% of total cohort

Types:

Population Cohorts

Member States:

France

Diseases:

Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A